The extensive study, executed in the laboratory of Dr. Patricia A. Hunt at Washington Condition University in Pullman, showed that BPA publicity affects the initial stages of egg creation in the ovaries of the developing mouse fetuses, thus suggesting that another era may suffer genetic defects in such biological procedures as mitosis and DNA replication. Furthermore, the WSU research group noted that their research exposed a striking down-regulation of mitotic/cell routine genes, raising the chance that BPA exposure instantly before meiotic access might work to shorten the reproductive lifespan of the feminine by reducing the full total pool of fetal oocytes.Related StoriesWeight loss and workout improve ovulation in ladies with polycystic ovary syndromeStudy displays restoring testosterone creation in men will not influence their fertilityTestosterone therapy not really associated with increased threat of aggressive prostate malignancy: StudyPipeline Upgrade On October 4, 2011, BioSante announced the completion of its two pivotal LibiGel Stage III efficacy trials. Trial data are being gathered from the 141 investigative sites in the U.S. And Canada that participated in the trials and the ongoing firm remains blinded to the outcomes. BioSante expects to announce top-line LibiGel efficacy outcomes from both trials in December 2011.